↓ Skip to main content

RNA interference approaches for treatment of HIV-1 infection

Overview of attention for article published in Genome Medicine, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)

Mentioned by

twitter
19 tweeters
facebook
5 Facebook pages

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
148 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
RNA interference approaches for treatment of HIV-1 infection
Published in
Genome Medicine, May 2015
DOI 10.1186/s13073-015-0174-y
Pubmed ID
Authors

Maggie L Bobbin, John C Burnett, John J Rossi

Abstract

HIV/AIDS is a chronic and debilitating disease that cannot be cured with current antiretroviral drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 replication and delay the onset of AIDS, viral mutagenesis often leads to viral escape from multiple drugs. In addition to the pharmacological agents that comprise cART drug cocktails, new biological therapeutics are reaching the clinic. These include gene-based therapies that utilize RNA interference (RNAi) to silence the expression of viral or host mRNA targets that are required for HIV-1 infection and/or replication. RNAi allows sequence-specific design to compensate for viral mutants and natural variants, thereby drastically expanding the number of therapeutic targets beyond the capabilities of cART. Recent advances in clinical and preclinical studies have demonstrated the promise of RNAi therapeutics, reinforcing the concept that RNAi-based agents might offer a safe, effective, and more durable approach for the treatment of HIV/AIDS. Nevertheless, there are challenges that must be overcome in order for RNAi therapeutics to reach their clinical potential. These include the refinement of strategies for delivery and to reduce the risk of mutational escape. In this review, we provide an overview of RNAi-based therapies for HIV-1, examine a variety of combinatorial RNAi strategies, and discuss approaches for ex vivo delivery and in vivo delivery.

Twitter Demographics

The data shown below were collected from the profiles of 19 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 148 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 45 30%
Student > Master 29 20%
Student > Ph. D. Student 20 14%
Researcher 13 9%
Student > Postgraduate 8 5%
Other 15 10%
Unknown 18 12%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 40 27%
Agricultural and Biological Sciences 38 26%
Immunology and Microbiology 14 9%
Chemistry 10 7%
Pharmacology, Toxicology and Pharmaceutical Science 8 5%
Other 18 12%
Unknown 20 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2021.
All research outputs
#2,226,193
of 21,790,947 outputs
Outputs from Genome Medicine
#520
of 1,380 outputs
Outputs of similar age
#30,734
of 250,471 outputs
Outputs of similar age from Genome Medicine
#1
of 1 outputs
Altmetric has tracked 21,790,947 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,380 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.4. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,471 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them